Skip to main content

Table 3 Results of the Cox regression analysis evaluating the breast cancer-specific survival (BCSS) and overall survival (OS) of patients with invasive lobular carcinoma (ILC)

From: A comparison of the clinical outcomes of patients with invasive lobular carcinoma and invasive ductal carcinoma of the breast according to molecular subtype in a Korean population

 

ILC (n = 528)

 

BCSS HR (95% CI)

P-value

OS HR (95% CI)

P-value

Age

    

<50

1

 

1

 

50≤

0.898 (0.424 to 1.904)

0.780

0.708 (0.350 to 1.435)

0.338

Surgery

    

mastectomy

1

 

1

 

breast conserving surgery

1.059 (0.520 to 2.157)

0.874

1.224 (0.645 to 2.324)

0.536

Tumor size

    

T ≤ 2 cm

1

 

1

 

2 cm < T ≤ 5 cm

0.524 (0.205 to 1.337)

0.176

0.507 (0.215 to 1.196)

0.121

5 cm < T

0.275 (0.055 to 1.367)

0.114

0.343 (0.077 to 1.527)

0.160

Nodal status

    

0

1

 

1

 

1 to 3

0.156 (0.216 to 1.232)

0.136

0.525 (0.244 to 1.128)

0.099

4 to 9

0.307 (0.074 to 1.267)

0.103

0.335 (0.090 to 1.250)

0.104

10≤

0.441 (0.103 to 1.886)

0.270

0.449 (0.116 to 1.737)

0.246

TNMstage

    

stage I

1

 

1

 

stage II

1.271 (0.634 to 2.548)

0.500

1.409 (0.753 to 2.639)

0.284

stage III

4.242 (2.023 to 8.897)

<0.001

3.647 (1.826 to 7.285)

<0.001

Molecular subtype

    

luminal A

1

 

1

 

luminal B

2.117 (0.903 to 4.961)

0.084

2.157 (0.977 to 4.764)

0.057

HER2-overexpression

1.499 (0.349 to 6.434)

0.586

1.769 (0.344 to 9.106)

0.495

Triple negative

3.543 (2.078 to 6.042)

<0.001

3.977 (1.653 to 9.565)

0.002

Lymphatic invasion

    

no

1

 

1

 

yes

0.732 (0.389 to 1.375)

0.332

0.802 (0.455 to 1.415)

0.446

Vascular invasion

    

no

1

 

1

 

yes

1.260 (0.690 to 0.299)

0.452

1.068 (0.608 to 1.875)

0.819

Estrogen receptor status

    

negative

1

 

1

 

positive

1.649 (0.464 to 5.859)

0.439

1.657 (0.482 to 5.697)

0.423

Progesterone receptor status

    

negative

1

 

1

 

positive

0.546 (0.277 to 1.076)

0.080

0.568 (0.318 to 1.014)

0.056

HER2

    

negative

1

 

1

 

positive

3.591 (0.353 to 36.498)

0.280

3.644 (0.395 to 33.657)

0.254

Radiation therapy

    

no

1

 

1

 

yes

0.844 (0.463 to 1.537)

0.579

0.795 (0.456 to 1.387)

0.419

Chemotherapy

    

no

1

 

1

 

yes

1.178 (0.466 to 2.977)

0.730

1.011 (0.453 to 2.259)

0.979

Hormonal therapy

    

no

1

 

1

 

yes

2.063 (0.826 to 5.153)

0.121

2.112 (0.952 to 4.688)

0.066

  1. BCSS, breast cancer-specific survival; HER2. human epidermal growth factor 2;HR, hazard ratio; ILC, invasive lobular carcinoma; OS, overall survival.